Ubrogepant
Treatment for Migraine
Typical Dosage: 50mg or 100mg oral
Effectiveness
75%
Safety Score
70%
Clinical Trials
21
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanideβ οΈ
Methπ
Cigarettesπ¬
Chemoβ’οΈ
AlcoholπΊ
Morphineπ
Antibioticsπ
Tylenolπ
Exerciseπ
Waterπ§
70
DangerousModerateSafe
Treatment Details
Dosage Range
50mg or 100mg oral
Time to Effect
1-2 hours
Treatment Duration
As needed
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10,000
Monitoring:$100
Side Effect Mgmt:$50
Total Annual:$10,150
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$280,000/QALY
QALYs Gained
0.06
Outcome-Based Costs
Cost per Responder
$18,455
Prescription Access Economics
Annual Societal Loss per Patient
$6,240
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$300/year
Time Cost
$200/year
Travel + wait time
Insurance Admin Cost
$240/year
Prior auth, claims
Rx Price
$10,000/year
Potential OTC Price
$2,500/year
Estimated if OTC available
Early Treatment Benefit
+0.05 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
LOWUbrogepant Outcomes
for Migraine
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+55%
Common Side Effects
Nausea
+5%
Somnolence
+3%
Dry mouth
+2%
Active Clinical Trials
7 active trials recruiting for Ubrogepant in Migraine
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
NCT06417775RECRUITINGPHASE3
496 participants
INTERVENTIONAL
Birmingham, United States +105 more
Started: Sep 10, 2024
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
NCT05127954ENROLLING BY INVITATIONPHASE3
1.2K participants
INTERVENTIONAL
Huntsville, United States +112 more
Started: Jan 14, 2022
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
NCT05125302RECRUITINGPHASE3
1.06K participants
INTERVENTIONAL
Huntsville, United States +121 more
Started: Jan 13, 2022
Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies
NCT05503082ACTIVE NOT RECRUITINGPHASE4
164 participants
INTERVENTIONAL
Chicago, United States +1 more
Started: Sep 6, 2022
Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada
NCT06692881RECRUITING
167 participants
OBSERVATIONAL
Calgary, Canada +12 more
Started: Feb 12, 2025
Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
NCT07310290NOT YET RECRUITING
189 participants
OBSERVATIONAL
Started: Dec 17, 2025
An Observational Study to Assess Ubrogepant Tablets and Atogepant Tablets to Treat Migraine in Adult Participants
NCT05827887ACTIVE NOT RECRUITING
200 participants
OBSERVATIONAL
Holon, Israel +10 more
Started: Jun 25, 2023
Completed Clinical Trials
12 completed trials for Ubrogepant in Migraine
Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine
NCT04818515COMPLETEDPHASE1
26 participants
INTERVENTIONAL
Orlando, United States +2 more
Started: Mar 17, 2021
Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin
NCT05654298COMPLETEDNA
20 participants
INTERVENTIONAL
Leuven, Belgium
Started: Mar 15, 2022
A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)
NCT01613248COMPLETEDPHASE2
834 participants
INTERVENTIONAL
Started: Jul 1, 2012
Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
NCT05264129COMPLETEDPHASE4
263 participants
INTERVENTIONAL
Birmingham, United States +36 more
Started: Mar 7, 2022
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
NCT04179474COMPLETEDPHASE1
40 participants
INTERVENTIONAL
Springfield, United States +1 more
Started: Sep 26, 2019
Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
NCT02867709COMPLETEDPHASE3
1.69K participants
INTERVENTIONAL
Birmingham, United States +108 more
Started: Aug 26, 2016
Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
NCT02828020COMPLETEDPHASE3
1.67K participants
INTERVENTIONAL
Mesa, United States +89 more
Started: Jul 22, 2016
A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
NCT06578585COMPLETEDPHASE1
43 participants
INTERVENTIONAL
Orlando, United States +3 more
Started: Sep 13, 2024
A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)
NCT01657370COMPLETEDPHASE2
195 participants
INTERVENTIONAL
Started: Aug 1, 2012
Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
NCT04492020COMPLETEDPHASE3
518 participants
INTERVENTIONAL
Birmingham, United States +72 more
Started: Aug 21, 2020
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
NCT02873221COMPLETEDPHASE3
1.25K participants
INTERVENTIONAL
Birmingham, United States +176 more
Started: Sep 13, 2016
An Observational Study to Assess Change in Disease Activity When Ubrogepant Tablets Are Combined With Atogepant Tablets to Treat Migraine in Adult Participants
NCT05653986COMPLETED
391 participants
OBSERVATIONAL
The Bronx, United States
Started: Dec 18, 2022
Showing 20 of 22 total trials